Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate

Multicenter study

Balasrinivasa R Sajja, Ponnada A. Narayana, J. S. Wolinsky, C. W. Ahn, William M. Brooks, Corey Ford, Todd Richards, James Bowen, J. William Lindsey, Yvan Boulanger, Pierre Duquette, Douglas L. Arnold

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Multicenter proton magnetic resonance spectroscopic imaging (MRSI) studies were performed on 58 primary progressive multiple sclerosis (PPMS) patients from four centers for investigating the efficacy of glatiramer acetate (GA) treatment. These patients were drawn from 943 subjects who participated in the PROMiSe trial. In these MRSI studies, patients were followed over a period of 3 years. MRSI data were acquired by all the, centers using the same pulse sequence, and spectral analysis was performed at a single site using a customized analysis software package. Quantitative metabolite ratios, N-acetyl aspartate (NAA)/ creatine (Cr) and choline (Cho)/Cr, were compared between GA-treated and placebo-treated PPMS patients. There was no significant difference in metabolite ratios between GA-treated and placebo-treated patients. The difference in metabolite ratios between the normal-appearing tissues (NAT) and lesion-containing regions (LCR) in GA treated patients was not significantly different from placebo treated patients. Strong lipid resonances, even in the absence of lesions, were observed on MRSI data in both gray matter and white matter in placebo- and GA-treated PPMS patients. No significant difference in number of patients with lipids between the two groups over a period of 3 years was found.

Original languageEnglish (US)
Pages (from-to)73-80
Number of pages8
JournalMultiple Sclerosis
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Chronic Progressive Multiple Sclerosis
Multicenter Studies
Magnetic Resonance Imaging
Placebos
Creatine
Lipids
Glatiramer Acetate
Choline
Sequence Analysis
Protons
Software

Keywords

  • Glatiramer acetate
  • MRI
  • MRSI
  • N-acetylaspartate
  • Primary progressive multiple sclerosis
  • Proton spectroscopic imaging

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate : Multicenter study. / Sajja, Balasrinivasa R; Narayana, Ponnada A.; Wolinsky, J. S.; Ahn, C. W.; Brooks, William M.; Ford, Corey; Richards, Todd; Bowen, James; Lindsey, J. William; Boulanger, Yvan; Duquette, Pierre; Arnold, Douglas L.

In: Multiple Sclerosis, Vol. 14, No. 1, 01.01.2008, p. 73-80.

Research output: Contribution to journalArticle

Sajja, BR, Narayana, PA, Wolinsky, JS, Ahn, CW, Brooks, WM, Ford, C, Richards, T, Bowen, J, Lindsey, JW, Boulanger, Y, Duquette, P & Arnold, DL 2008, 'Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: Multicenter study', Multiple Sclerosis, vol. 14, no. 1, pp. 73-80. https://doi.org/10.1177/1352458507079907
Sajja, Balasrinivasa R ; Narayana, Ponnada A. ; Wolinsky, J. S. ; Ahn, C. W. ; Brooks, William M. ; Ford, Corey ; Richards, Todd ; Bowen, James ; Lindsey, J. William ; Boulanger, Yvan ; Duquette, Pierre ; Arnold, Douglas L. / Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate : Multicenter study. In: Multiple Sclerosis. 2008 ; Vol. 14, No. 1. pp. 73-80.
@article{24b8ea250a91489492bcafdf07e2900c,
title = "Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: Multicenter study",
abstract = "Multicenter proton magnetic resonance spectroscopic imaging (MRSI) studies were performed on 58 primary progressive multiple sclerosis (PPMS) patients from four centers for investigating the efficacy of glatiramer acetate (GA) treatment. These patients were drawn from 943 subjects who participated in the PROMiSe trial. In these MRSI studies, patients were followed over a period of 3 years. MRSI data were acquired by all the, centers using the same pulse sequence, and spectral analysis was performed at a single site using a customized analysis software package. Quantitative metabolite ratios, N-acetyl aspartate (NAA)/ creatine (Cr) and choline (Cho)/Cr, were compared between GA-treated and placebo-treated PPMS patients. There was no significant difference in metabolite ratios between GA-treated and placebo-treated patients. The difference in metabolite ratios between the normal-appearing tissues (NAT) and lesion-containing regions (LCR) in GA treated patients was not significantly different from placebo treated patients. Strong lipid resonances, even in the absence of lesions, were observed on MRSI data in both gray matter and white matter in placebo- and GA-treated PPMS patients. No significant difference in number of patients with lipids between the two groups over a period of 3 years was found.",
keywords = "Glatiramer acetate, MRI, MRSI, N-acetylaspartate, Primary progressive multiple sclerosis, Proton spectroscopic imaging",
author = "Sajja, {Balasrinivasa R} and Narayana, {Ponnada A.} and Wolinsky, {J. S.} and Ahn, {C. W.} and Brooks, {William M.} and Corey Ford and Todd Richards and James Bowen and Lindsey, {J. William} and Yvan Boulanger and Pierre Duquette and Arnold, {Douglas L.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1177/1352458507079907",
language = "English (US)",
volume = "14",
pages = "73--80",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate

T2 - Multicenter study

AU - Sajja, Balasrinivasa R

AU - Narayana, Ponnada A.

AU - Wolinsky, J. S.

AU - Ahn, C. W.

AU - Brooks, William M.

AU - Ford, Corey

AU - Richards, Todd

AU - Bowen, James

AU - Lindsey, J. William

AU - Boulanger, Yvan

AU - Duquette, Pierre

AU - Arnold, Douglas L.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Multicenter proton magnetic resonance spectroscopic imaging (MRSI) studies were performed on 58 primary progressive multiple sclerosis (PPMS) patients from four centers for investigating the efficacy of glatiramer acetate (GA) treatment. These patients were drawn from 943 subjects who participated in the PROMiSe trial. In these MRSI studies, patients were followed over a period of 3 years. MRSI data were acquired by all the, centers using the same pulse sequence, and spectral analysis was performed at a single site using a customized analysis software package. Quantitative metabolite ratios, N-acetyl aspartate (NAA)/ creatine (Cr) and choline (Cho)/Cr, were compared between GA-treated and placebo-treated PPMS patients. There was no significant difference in metabolite ratios between GA-treated and placebo-treated patients. The difference in metabolite ratios between the normal-appearing tissues (NAT) and lesion-containing regions (LCR) in GA treated patients was not significantly different from placebo treated patients. Strong lipid resonances, even in the absence of lesions, were observed on MRSI data in both gray matter and white matter in placebo- and GA-treated PPMS patients. No significant difference in number of patients with lipids between the two groups over a period of 3 years was found.

AB - Multicenter proton magnetic resonance spectroscopic imaging (MRSI) studies were performed on 58 primary progressive multiple sclerosis (PPMS) patients from four centers for investigating the efficacy of glatiramer acetate (GA) treatment. These patients were drawn from 943 subjects who participated in the PROMiSe trial. In these MRSI studies, patients were followed over a period of 3 years. MRSI data were acquired by all the, centers using the same pulse sequence, and spectral analysis was performed at a single site using a customized analysis software package. Quantitative metabolite ratios, N-acetyl aspartate (NAA)/ creatine (Cr) and choline (Cho)/Cr, were compared between GA-treated and placebo-treated PPMS patients. There was no significant difference in metabolite ratios between GA-treated and placebo-treated patients. The difference in metabolite ratios between the normal-appearing tissues (NAT) and lesion-containing regions (LCR) in GA treated patients was not significantly different from placebo treated patients. Strong lipid resonances, even in the absence of lesions, were observed on MRSI data in both gray matter and white matter in placebo- and GA-treated PPMS patients. No significant difference in number of patients with lipids between the two groups over a period of 3 years was found.

KW - Glatiramer acetate

KW - MRI

KW - MRSI

KW - N-acetylaspartate

KW - Primary progressive multiple sclerosis

KW - Proton spectroscopic imaging

UR - http://www.scopus.com/inward/record.url?scp=42149098368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149098368&partnerID=8YFLogxK

U2 - 10.1177/1352458507079907

DO - 10.1177/1352458507079907

M3 - Article

VL - 14

SP - 73

EP - 80

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 1

ER -